Novo Nordisk makes impairment loss of $816 million in Q2 By Reuters

COPENHAGEN (Reuters) – Novo Nordisk (NYSE:) said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to meet its primary endpoint.

($1 = 6.9791 Danish crowns)